MedPath

Chlorhexidine Lavage for Recurrent Urinary Tract Infection

Phase 4
Recruiting
Conditions
Urinary Tract Infections
Recurrent Urinary Tract Infection
Interventions
Registration Number
NCT06598514
Lead Sponsor
Oregon Health and Science University
Brief Summary

A two-arm randomized control trial evaluating rates of urinary tract infection in post-menopausal women on vaginal estrogen with recurrent urinary tract infections.

Detailed Description

There is a critical need for low-cost, non-antibiotic interventions that are feasible for patients to utilize for risk reduction and prevention of recurrent urinary tract infections (UTIs). The current most effective non-antibiotic prophylaxis for recurrent UTI is vaginal estrogen; however, approximately 50% of women will continue to experience UTIs. We propose a randomized control trial of postmenopausal women on vaginal estrogen with the diagnosis of recurrent UTIs to evaluate a novel post-defecation hygienic strategy utilizing a 2% chlorhexidine perineal lavage. Participants will be randomized to either a 2% chlorhexidine perineal lavage or a water lavage. Study participants will be followed for up to 6-months, and UTIs will be tracked with culture proven samples throughout study participation.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
136
Inclusion Criteria
  • Post-menopausal female between age 55 and 89
  • No post-menopausal bleeding
  • Diagnosis of recurrent urinary tract infection (UTI) in the electronic health record or as two culture proven UTIs in 6 months or three culture proven UTIs in 12 months
  • At least one UTI in the 6 months prior to entering the study
  • Asymptomatic for UTI symptoms at the time of enrollment.
  • On vaginal estrogen therapy for at least 6 weeks prior to enrollment
  • Ready access to email and internet
Exclusion Criteria
  • Recent prophylactic antibiotic use (washout period of 4 weeks)
  • Neurogenic bladder
  • Diagnosis of urinary retention
  • Uncorrected Stage III-IV prolapse
  • Indwelling catheter or need for intermittent self-catheterization
  • History of complicated UTIs
  • History of interstitial cystitis or bladder pain syndrome
  • History of fecal incontinence/accidental bowel leakage
  • Greater than 14 bowel movements per week
  • Non-English speaking
  • Allergy to chlorhexidine gluconate
  • Inability to utilize vaginal estrogen therapy
  • Recent urogynecological or urologic surgery (<12 weeks)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Chlorhexidine LavageChlorhexidine2% chlorhexidine perineal lavage following defecation
Sterile Water LavageSterile WaterSterile water perineal lavage following defecation
Primary Outcome Measures
NameTimeMethod
Rate of Urinary Tract Infection (UTI)90 days following treatment initiation

The proportion of participants in each arm who experience a urinary tract infection (UTI) within 90 days will be compared

Secondary Outcome Measures
NameTimeMethod
Vulvovaginal Symptom Questionnaire (VSQ)VSQ administered prior to randomization and at 6 weeks, 12 weeks, and 24 weeks post-randomization

Vulvovaginal symptoms will be evaluated using the VSQ from baseline to post-intervention and compared between the groups with and without chlorhexidine in their perineal lavage. The VSQ is scored on a scale of 0-16 for those who are not sexually active or 0-20 for those who are sexually active, with a higher score indicating worse outcomes.

Urinary Distress Inventory (UDI-6)UDI-6 administered prior to randomization and at 6 weeks, 12 weeks, and 24 weeks post-randomization

Urinary symptoms will be evaluated using the UDI-6 from baseline to post-intervention and compared between the groups with and without chlorhexidine in their perineal lavage. It is scored on a scale from 0 to 100 with higher scores indicating worse outcomes.

Trial Locations

Locations (1)

Oregon Health & Science University

🇺🇸

Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath